Pharmaceuticals
Weakness After Protracted Upside Move Causes Discomfort
Some traders seem unsettled by a bit of downside volatility after not experiencing much of it of late.
Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal
Are the technical and quantitative approaches on the same page?
UnitedHealth Group Can Pull Back in the Short Run So Look to Buy the Dip
Time to review the charts and indicators.
Global Blood Therapeutics Is Poised to Rally Further in the Months Ahead
GBT is dedicated to discovering, developing, and commercializing ways to treat blood disorders.
Bullish Looking Jazz Pharmaceutical Gets a Boost From a Quant Buy Recommendation
Let's review the charts and indicators of this Dublin-based biopharmaceutical.
Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.
GlaxoSmithKline Could Rise 20% From Here
Shares of the pharma company have broken out on our Point and Figure chart.
Kura Oncology Requires Plenty of Patience by Investors
Our technical outlook and strategy for the San Diego-based biotech.